Please select the option that best describes you:
Topics:
Breast Cancer • Medical Oncology • MD Anderson • NCI-CCC Tumor Board Question • Neoadjuvant chemotherapy • Her2+ • NCI-CCC Breast Tumor Board Question
How do you manage a HR-/HER2+ breast cancer patient with local progression during neoadjuvant TCHP?
How would you approach additional systemic therapy? Would the clinical stage of the cancer affect your management?
Answer from: Medical Oncologist at Community Practice
With the robust activity of HER2-targeted agents in the operable setting, this is a highly concerning clinical scenario. I would retest for HER2 on the biopsy specimen and confirm its positivity. Also, I have significantly limited the use of anthracyclines in patients with HER2+ breast cancer - give...
Sign in or Register to read more